News

NEWS ABOUT THE AMBRYSHARE

ALISO VIEJO, CALIF., February 21st, 2017—Ambry Genetics (Ambry) has created an online portal to enable more patients and families to participate in research through the AmbryShare program. With this simplified portal, Ambry has streamlined the research consent process to make cohort recruitment easier for clinicians at the time of sample collection for clinical testing.
Patients now have the flexibility to e-consent from home, or a mobile device during their office visits. An individual can...

ALISO VIEJO, CALIF., January 18, 2017—Ambry Genetics’ (Ambry) data sharing program, AmbryShare, is one of the largest germline exome data sets on hereditary breast and ovarian cancer available, with more than 1 million variants from 11,400 patients. This repository, originally announced in March of 2016 and previously only available to select researchers, is now publicly available for download.
Comprised of de-identified aggregated allele frequency data that includes analysis of all 20,000+...

Original post can be found here.
ALISO VIEJO – Charles Dunlop, founder and CEO of Ambry Genetics, never tested his own DNA even though he had the technology at his fingertips. He refused to displace a vial of a patient’s blood in a lab bursting at capacity.
But after his 2014 diagnosis of Stage 4 prostate cancer, he ran a sample and discovered a mutation in a gene involved in DNA repair, which can increase risk for a number of cancers.
“I had a lab over here for people like me and...

One of the most powerful lessons I learned when I was a medical resident leading a ward team was the incredible clarifying power of focusing on the patient. I found it profoundly moving how many turf battles and care debates could be resolved almost magically by aligning everyone around the basic question, “What’s in the best interest of the patient in front of us?”
Unfortunately, as scope expands from ward to hospital to health system to healthcare, the challenges of alignment get progressively...

Genetic information from 10,000 individuals with breast or ovarian cancer is now available online for free, courtesy of Ambry Genetics, a leading DNA testing company.
“This was a conservative first step to … break the mold and get moving toward the direction of the beginning of the end of human disease,” Ambry chief executive Charles Dunlop told STAT.
The initiative is designed to advance the field of precision medicine, in which treatments are tailored to the specific genetic makeup...

Cancer data is going open source.
When a breast cancer patient goes in for genomic testing, data usually gets locked away in a patient file.
But on Tuesday, genomic testing company Ambry Genetics released anonymized data on genetic profiles of thousands of its breast and ovarian cancer patients.
The database, called AmbryShare, is free and open to the public. In other words, it’s a big catalogue where researchers, doctors, or patients can seek out genetic patterns in cancer data.
Get Data...

Cancer-screening firm Ambry Genetics is giving away anonymized data on 10,000 breast and ovarian cancer patients to researchers.
Who owns our genetic heritage? It's a contentious question in the multi-billion-dollar genetics industry. Scientists now know not only all three billion-plus letters of the human genome, but many of the key genes that cause hereditary ailments including cancers, autism, Down syndrome, and Parkinson's. That's expensive knowledge, and some firms and institutions that...

Original post can be found here.
In an unusual move, a leading genetic testing company is making genetic information from the people it has tested publicly available, a move the company says could make a large trove of data available to researchers looking for genes linked to various diseases.
The company, Ambry Genetics, is expected to announce on Tuesday that it will put information from 10,000 of its customers into a database called AmbryShare.
“We’re going to discover a lot of new...